Rheumatology in 2030: a lively conversation between two Benelux key opion leaders in rheumatology.
Check it out and click here below to get a short flavour of the podcasts.
20 November 2020
European Commission has approved TREMFYA® ▼ (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate
response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.
16 October 2020
Janssen Receives CHMP Positive Opinion for Expanded Use of TREMFYA® ▼ (guselkumab) in the Treatment of Active Psoriatic Arthritis (PsA) in the European Union (EU).
14 July 2020
TREMFYA® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis.
20 October 2019
Janssen Seeks to Expand Use of TREMFYA® ▼ (guselkumab) in the Treatment of Adults with Active Psoriatic Arthritis.
Do you have a question for us or did you not find what you were looking for? Let us know and one of our Janssen's specialists will contact you as soon as possible.
Discover here the Janssen's portfolio and product SmPC's.
On this page you will find interactive 3D animations of the human anatomy and various syndromes. This allows you to zoom in on the anatomy, tissue structures, disease mechanisms and the course of the disease.